An interventional study of SCOUT-Assisted Review Workflow and Standard Manual Review Workflow in Coronary Heart Disease (CHD), sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, and was the 22nd registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–45
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–45
By country, each count listing its studies:
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 240 across the 13 interventional studies, 5,000 across the 12 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
4 of the studies in Coronary Disease by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07230847China National Center for Cardiovascular DiseasesA Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography | 2026-12-31 |
| NCT07766551China National Center for Cardiovascular DiseasesConstruction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI) | 2027-01-01 |
| NCT07004452China National Center for Cardiovascular DiseasesMulti-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multi-reader, randomized crossover trial evaluates SCOUT (Scalable Clinical Oversight via Uncertainty Triangulation), a model-agnostic meta-verification framework that selectively defers unreliable large language model (LLM) predictions to clinicians by triangulating three orthogonal uncertainty signals: model heterogeneity, stochastic inconsistency, and reasoning critique. The trial assesses whether SCOUT-assisted review can reduce physician review time compared with standard manual review of AI-generated diagnoses while maintaining non-inferior diagnostic accuracy in coronary heart disease (CHD) subtyping.
Background: Large language models are increasingly deployed in clinical workflows, yet requiring clinician review of every AI output negates the efficiency gains that motivate their adoption. SCOUT addresses this efficiency-safety paradox through algorithmic meta-verification.
The SCOUT framework triangulates three orthogonal external signals to determine case-level uncertainty: (1) Model Heterogeneity - whether a structurally different auxiliary LLM agrees with the primary model; (2) Stochastic Inconsistency - whether repeated sampling from the same model yields divergent outputs; (3) Reasoning Critique - whether an external checker model identifies logical flaws in the chain-of-thought reasoning.
In this crossover trial, 7 clinicians of varying seniority (2 junior residents, 3 senior residents, 2 attending physicians) each review all 110 cases under both standard manual review and SCOUT-assisted review workflows. The study evaluates workflow efficiency (primary endpoint) and diagnostic accuracy (secondary endpoint).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Physicians manually review all cases in the control set (n=54) with access to AI predictions and reasoning. No selective deferral.
Diagnostic Test: Standard Manual Review Workflow
Physicians process the intervention set (n=56) through the SCOUT framework. Low-uncertainty cases are auto-accepted; high-uncertainty cases undergo physician review with full audit trail.
Diagnostic Test: SCOUT-Assisted Review Workflow
SCOUT-Assisted Review (Intervention Arm): Physicians review 56 cases processed through the SCOUT framework. For cases classified as low-uncertainty (D(x)=0), the AI prediction is auto-accepted without physician review. For high-uncertainty cases (D(x)=1), the physician reviews the case with access to the main model's chain-of-thought reasoning and the meta-verification audit results. The main model is DeepSeek-V3.1 with chain-of-thought prompting.
Physicians perform a full manual review of 54 cases using raw medical records with access to the AI model's predictions and reasoning, but without SCOUT uncertainty stratification or selective deferral.
Mean physician review time per case (minutes)
Mean time spent by each clinician reviewing and rendering a diagnostic decision per case under each arm. Measured in minutes.
Time frame: Through study completion, an average of 2 hours.
Diagnostic accuracy (%)
Proportion of correct CHD subtype classifications (STEMI, NSTEMI, unstable angina, chronic coronary syndromes) under each arm.
Time frame: Through study completion, an average of 2 hours.
Computational Return on Investment (ROI)
Ratio of physician time savings (valued at standardized minute-wages from Sanming healthcare reform benchmarks) to computational cost of SCOUT inference, stratified by clinician seniority level.
Time frame: Through study completion, an average of 2 hours.
Plan to share: Yes — De-identified individual participant data underlying the results reported in this study will be made available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 1 months after publication of the primary results and available for up to 60 months.
Access criteria: Data are available from the corresponding author upon reasonable request. Requestors will need to provide a methodologically sound research proposal and sign a data use agreement.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Feb 2026, 0 months.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 0 months is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →